Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 20,000 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 20,000 shares of Moderna stock in a transaction dated Monday, September 13th. The shares were sold at an average price of $447.41, for a total transaction of $8,948,200.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Stephen Hoge also recently made the following trade(s):

  • On Thursday, September 2nd, Stephen Hoge sold 10,000 shares of Moderna stock. The shares were sold at an average price of $393.13, for a total transaction of $3,931,300.00.
  • On Friday, August 13th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $405.00, for a total transaction of $6,075,000.00.
  • On Friday, July 23rd, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $335.13, for a total transaction of $5,026,950.00.
  • On Monday, July 26th, Stephen Hoge sold 5,000 shares of Moderna stock. The stock was sold at an average price of $351.99, for a total transaction of $1,759,950.00.
  • On Tuesday, July 13th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $238.87, for a total transaction of $3,583,050.00.
  • On Tuesday, July 6th, Stephen Hoge sold 10,000 shares of Moderna stock. The shares were sold at an average price of $229.62, for a total transaction of $2,296,200.00.
  • On Wednesday, June 23rd, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $216.20, for a total transaction of $3,243,000.00.

Shares of NASDAQ MRNA opened at $427.71 on Wednesday. The stock has a market capitalization of $172.64 billion, a price-to-earnings ratio of 53.33, a PEG ratio of 0.53 and a beta of 1.48. Moderna, Inc. has a 12 month low of $63.64 and a 12 month high of $497.49. The firm’s 50 day simple moving average is $365.45 and its 200-day simple moving average is $238.96. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.24 and a quick ratio of 1.17.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 5th. The company reported $6.46 EPS for the quarter, topping analysts’ consensus estimates of $6.01 by $0.45. The business had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Moderna had a net margin of 49.79% and a return on equity of 88.13%. The business’s revenue was up 6457.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.31) EPS. Analysts anticipate that Moderna, Inc. will post 29.17 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Capital Analysts LLC purchased a new position in shares of Moderna during the 1st quarter valued at approximately $26,000. Evermay Wealth Management LLC purchased a new position in shares of Moderna during the 2nd quarter valued at approximately $28,000. OLD Second National Bank of Aurora purchased a new position in shares of Moderna during the 1st quarter valued at approximately $29,000. Winch Advisory Services LLC lifted its position in shares of Moderna by 1,785.7% during the 2nd quarter. Winch Advisory Services LLC now owns 132 shares of the company’s stock valued at $31,000 after buying an additional 125 shares in the last quarter. Finally, Certified Advisory Corp purchased a new position in shares of Moderna during the 1st quarter valued at approximately $33,000. 55.89% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the stock. Argus upped their price target on shares of Moderna from $200.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, June 24th. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 5th. Zacks Investment Research downgraded shares of Moderna from a “buy” rating to a “hold” rating and set a $330.00 price objective on the stock. in a report on Monday, July 19th. Jefferies Financial Group upped their price objective on shares of Moderna from $170.00 to $250.00 and gave the company a “hold” rating in a report on Thursday, July 15th. They noted that the move was a valuation call. Finally, Piper Sandler downgraded shares of Moderna from an “overweight” rating to a “neutral” rating in a report on Friday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $205.21.

About Moderna

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: Death Cross

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.